ARIAD Pharma (NASDAQ: ARIA) announced the issuance of its first U.S. patent on brigatinib, ARIAD’s investigational ALK inhibitor. The United ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE